Objective. To compare the antihypertensive effect of treatment with zofenopril vs candesartan by office and ambulatory blood pressure (BP). Design and methods. Following a 2-week wash-out from previous treatment, 236 grade I-II primary hypertensive patients were randomized double-blind to 12 weeks treatment with zofenopril 30 mg or candesartan 8 mg od. After 4 weeks, treatment was doubled in responder non-normalized (office systolic BP≥140 mmHg and office diastolic BP reduction ≥10 mmHg) or non-responder patients (office systolic BP≥140 mmHg and office diastolic BP reduction <10 mmHg). Following a further 4 weeks, non-responder non-normalized patients were withdrawn. Results. In the intention-to-treat population, office systolic BP and diastolic BP reductions after 12 weeks of treatment were similar between the two groups (zofenopril: 21±11/15±8 mmHg, n=114 vs C: 20±11/15±7 mmHg (candesartan; p=NS). Also 24-h ambulatory BPs were equally reduced by zofenopril and candesartan (7±13/ 5±8 mmHg vs 7±12/5±8 mmHg; p=NS). The trough-to-peak ratio and smoothness index were not sigficantly different between zofenopril and candesartan. Tolerability of both drugs was good. Conclusions. Monotherapy with zofenopril and candesartan similary reduced office and 24-h BPs. Since almost 90% of patiens were normalized by either zofenopril or candesartan, this result suppots the importance of considering low- or high-dose monotherapies as initial for most hypertensive patients of mild degree.

A similar 24-h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients

FRANZONI, FERDINANDO;
2006-01-01

Abstract

Objective. To compare the antihypertensive effect of treatment with zofenopril vs candesartan by office and ambulatory blood pressure (BP). Design and methods. Following a 2-week wash-out from previous treatment, 236 grade I-II primary hypertensive patients were randomized double-blind to 12 weeks treatment with zofenopril 30 mg or candesartan 8 mg od. After 4 weeks, treatment was doubled in responder non-normalized (office systolic BP≥140 mmHg and office diastolic BP reduction ≥10 mmHg) or non-responder patients (office systolic BP≥140 mmHg and office diastolic BP reduction <10 mmHg). Following a further 4 weeks, non-responder non-normalized patients were withdrawn. Results. In the intention-to-treat population, office systolic BP and diastolic BP reductions after 12 weeks of treatment were similar between the two groups (zofenopril: 21±11/15±8 mmHg, n=114 vs C: 20±11/15±7 mmHg (candesartan; p=NS). Also 24-h ambulatory BPs were equally reduced by zofenopril and candesartan (7±13/ 5±8 mmHg vs 7±12/5±8 mmHg; p=NS). The trough-to-peak ratio and smoothness index were not sigficantly different between zofenopril and candesartan. Tolerability of both drugs was good. Conclusions. Monotherapy with zofenopril and candesartan similary reduced office and 24-h BPs. Since almost 90% of patiens were normalized by either zofenopril or candesartan, this result suppots the importance of considering low- or high-dose monotherapies as initial for most hypertensive patients of mild degree.
2006
Leonetti, G. Ad; Rappelli, ; Ab, A. B; Omboni, ; Sc, S. C; Ansuini, ; Re, R. E; Acquarone, ; Nf, N. F; Antonucci, ; Ef, E. F; Campanini, ; Mg, M. G; Paracchini, ; Eg, E. G; Celegon, ; Lh, L. H; Lazzari, ; Fi, F. I; Crippa, ; Mi, M. I; Caruso, ; Dj, D. J; D'Avino, ; Mj, M. J; Biase, Di; Mk, M. K; Manuppelli, ; Vk, V. K; Pellegrino, ; Plk, P. L. K; Etna, ; Nl, N. L; Fiorentini, ; Cm, C. M; Lucreziotti, ; Sm, S. M; Galetta, ; Fn, F. N; Franzoni, Ferdinando; Fn, F. N; Femia, ; Rn, R. N; Giovannetti, ; Ro, R. O; Auteri, ; Ap, A. P; Bruni, ; Fp, F. P; Leo, ; Ap, A. P; Lonati, ; Lm, L. M; Magnaghi, ; Gcm, G. C. M; Sensale, ; Pj, P. J; Maiolica, ; Oj, O. J; Malinverni, ; Cq, C. Q; Mangiameli, ; Sr, S. R; Cardillo, ; Rr, R. R; Antonelli, ; As, A. S; Mazzotta, ; Ls, L. S; Nami, ; Rp, R. P; Salvo, ; Dpp, D. P. P; Pezzotti, ; Up, U. P; Monti, ; Gt, G. T; Novati, ; Pt, P. T; Furlan, ; Rm, R. M; Perego, ; Fm, F. M; Pede, ; Su, S. U; Pico, ; Cu, C. U; Renna, ; Au, A. U; Margonato, ; Av, A. V; Pizzetti, ; Rv, R. V; Prinzi, ; Dw, D. W; Smimmo, ; Dw, D. W; Cicco, De; Gw, G. W; Napolitano, ; Gw, G. W; Reynaud, ; Mx, M. X; Piccoli, ; Mx, M. X; Cipollari, ; Gx, G. X; Saccà, ; Plj, P. L. J; Oliviero, ; Uj, U. J; Ettari, ; Elj, E. L. J; Scanferla, ; Fy, F. Y; Rosato, ; Gz, G. Z; Siano, ; Fz, F. Z; Cianciucci, ; Gmz, G. M. Z; Pagliuca, ; Mrz, M. R. Z; Santucci, ; Aaa, A. Aa; Ferri, ; Caa, C. Aa; Desideri, ; Gbaa, G. B. Aa; Zingaretti,
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/816340
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? ND
social impact